INTRODUCTION
STARD and QUADAS scores of studies of CA 125, CA 15-3, CA 19-9, and CYFRA 21-1, are outlined in Appendix Table 2, Appendix Table 3, Appendix Table 4, and Appendix Table 5 (available at http://thorax.bmj.com/supplemental), respectively. The average samples size of CA 125, CA 15-3, CA 19-9, and CYFRA 21-1 studies was 131 (range 41 -416), 162 (range 39 -416), 138 (range 61 -336), and 127 (range 35 -416), respectively. In the present meta-analysis, all patients with pleural malignancies were confirmed based on the conventional "gold standard," MPE was demonstrated by cytologic study, pleural biopsy specimen, or autopsy. Table 1 .
Diagnostic accuracy
The sensitivity of pleural CA-125 measurement in the diagnosis of MPE varied between 0.17 and 1.00, and the specificity varied between 0.05 and 1.00. We noted that PLR was 5.96 (range 1.06 -85.67), NLR was 0.54 (range 0.02 -0.83), and DOR was 19.61 (range 2.14 -731.00). For CA 15-3, the sensitivity ranged from 0.30 to 0.80, while specificity ranged from 0.75 -1.00. We noted that PLR was 11.69 (range 2.05 -151.80), NLR was 0.52 (range 0.22 -0.70), and DOR was 24.74 (range 3.15 -224.00). For CA 19-1, the sensitivity ranged from 0.13 to 0.89, while specificity ranged from 0.73 -1.00. We noted that PLR was 10.42 (range 1.42 -58.50), NLR was 0.70 (range 0.11 -0.87), and DOR was 19.88 (range 1.69 -348.50).
For CYFRA 21-1, the sensitivity ranged from 0.20 to 0.91, while specificity ranged from 0.08 -1.00. We noted that PLR was 6.55 (range 0.99 -103.43), NLR was 0.43 (range 0.10 -0.1.18), and DOR was 16 .24 (range 0.83 -130.02).
As shown in Table 1 , all Q values for sensitivity, specificity, PLR, NLR, and DOR of studies of all tumor markers were high, with all p-values less than 0.0001, indicating significant heterogeneities between all studies.
The SROC curve and its area under curve (AUC) present an overall summary of test performance, and display the trade off between sensitivity and specificity. In all 29 studies included in the present meta-analysis, both sensitivity and specificity were indicated directly in each publication, and a single optimal cut-off value was selected by all investigators and was reported in their publications, respectively. The present meta-analysis has shown that the mean values of the maximum joints sensitivity and specificity of CA 125, CA 15-3, CA 19-9, and CYFRA 21-1 were 0.81, 0.68, 0.72, and 0.76, respectively, and that their mean AUCs were 0.88, 0.73, 0.78, and 0.83, respectively, indicating the overall accuracy were not as high as expected.
In the publications included in the present meta-analysis, some studies performed evaluation of the simultaneous determination of two or more pleural tumor markers in the diagnosis of MPE. The pooled results of diagnostic accuracy of the combination of two or more tumor markers of CA 125, CA 15-3, CA 19-9, CYFRA 21-1 and CEA are shown in Table   2 . Our data showed that various tumor marker combinations resulted in a greater diagnostic role than that of one tumor marker alone.
Multiple regression analysis and publication bias
The scores of both STARD and QUADAS were used in the metaregression analysis to assess the effect of study quality on RDOR of CA 125, CA 15-3, CA 19-9, and CYFRA 21-1 in the diagnoses of MPE. Table 3 shows findings of metaregression analysis of the RDOR (dependent variable) between studies with higher and lower study quality scores. As shown in Table 3 , The CA 125 assays with higher quality (STARD ≥ 13) produced RDOR that were not significantly higher than the studies with lower quality (STARD < 13). Also, the studies with QUADAS ≥ 10 did not have a better performance than those studies with QUADAS < 10.
Similar to the findings of CA 125 studies, in the studies of CA 15-3, CA19-9, and CYFRA 21-1, we did not observe the studies with higher quality had a better test performance than those with lower quality. We also noted that differences for studies with or without blinded design, cross-sectional, consecutive/random and prospective design did not reach statistical significance (data not shown). These results indicated that the study quality and design did not substantially affect the accuracy of pleural tumor markers in the diagnosis of MPE. The overall specificity of CA 15-3, CA 19-9 and CYFRA 21-1, but not CA 125, was more than 0.90. The summary estimate of sensitivities for four tumor markers, however, were all quite low, and were more variable than specificity. These data suggest potential roles for these tumor marker determinations in confirming (ruling in) MPE. However, these tests maximize specificity at the cost of sensitivity, and this trade off has significant clinical implications. By contrast with the higher specificity, these tumor markers had low sensitivities that were not sufficiently low to exclude non-MPE when a patient's pleural tumor marker concentrations are lower than the cut-off values. The negative tests, therefore, do not mean absence of MPE, and patients with negative tumor marker results have a fairly high chance of having MPE.
The SROC curve presents a global summary of test performance, and shows the trade off between sensitivity and specificity. As a global measure of test efficacy we used the maximum joint sensitivity and specificity, the intersection point of the SROC curve with a diagonal line from the left upper corner to the right lower corner of the SROC space, which corresponds to the highest common value of sensitivity and specificity for the test (14) . This point does not indicate the only or even the best combination of sensitivity and specificity for a particular clinical setting, but represents an overall measure of the discriminatory power of a test. Our CYFRA 21-1 was negative, the probability that this patient has MPE is about 54%, 52%, 70%, and 43%, respectively, which is too high to rule out MPE.
In addition to the four tumor markers analyzed in the present meta-analysis, the other biomarkers such as CEA (25), neuron-specific enolase (26), CA 549 and CA72-4 (A23), etc., have been evaluated for their diagnostic performance for MPE. In a recent meta-analysis, we have found that the summary estimates for CEA in the diagnosis of MPE were: sensitivity 0.54 (95% CI 0.52 -0.55), specificity 0.94 (95% CI 0.93-0.95), PLR 9.52 (95% CI 6.97 -13.01), NLR 0.49 (95% CI 0.44 -0.54), and DOR 22.5 (95% CI 15.6 -32.5) (our unpublished manuscript). In the present meta-analysis, we found that the combination of two or more of CA 125, CA 15-3, CA 19-9, CYFRA 21-1, as well as CEA, resulted in a greater sensitivity than that of any one of the above tumor markers alone.
An exploration of the reasons for heterogeneity rather than computation of a single summary measure are an important goal of meta-analysis (27) The regression coefficients for the variables give a measure of the difference in diagnostic accuracy of tumor markers in the two groups, with positive coefficients indicating better discriminating power and negative coefficients corresponding to reduced discriminatory ability. In our meta-analysis, for all four tumor makers analyzed, both STARD and QUADAS scores were used in the metaregression analysis to assess the effect of study quality on RDOR. We did not observe the studies with higher quality had a better test performance than those with lower quality, although we found a significant heterogeneity for sensitivity, specificity, PLR, NLR, and DOR between these studies. We also noted that differences for studies with or without blinded design, cross-sectional, consecutive/random and prospective design did not reach statistical significance.
Our meta-analysis had some limitations. Firstly, noninclusion of conference abstracts, letters to the journal editors, and non-English language studies may have led to publication bias, an inflation of accuracy estimates due to preferential acceptance of papers reporting favorable results. Actually, we did observe potential for publication biases in studies included in the present meta-analysis. Secondly, we did not address issues such as cost-effectiveness, reliability, the incremental benefit of adding tumor marker assays to other tests, and the net effect of tumor marker assays on clinical care and patient outcomes. Also, because of lack of required data reported in the original publications, we could not analyze the effect of factors such as laboratory infrastructure, expertise with tumor marker assay technology, patient spectrum, and setting on the accuracy of tumor marker assays.
The accuracy of tumor marker determinations for MPE seems to be similar to those of conventional tests such as cytological examination-high specificity and low sensitivity. This similarity might make tumor markers less useful in practice because they do not have test properties that complement the properties of conventional tests. Based on the findings in our meta-analysis, we did not have reasons to recommend using any one tumor marker alone for the diagnosis of MPE. On the other hand, it should be mentioned that so far, there were no sufficient related studies for accurate evaluating the diagnostic accuracy of the combination of two or more tumor markers in MPE.
In conclusion, current evidence suggest that CA 15-3, CA 19-9, and CYFRA 21-1 are highly specific but insufficiently sensitive to diagnose MPE, and the combination of two or more tumor markers seems to be more sensitive. Based on our data, we think that every patient The abbreviations refer to Table 1 , and NA = not applicable. 
Appendix statistical methods
For meta-analysis of diagnostic tests, a summary receiver operating characteristic (SROC) curve was constructed. We convert the true positive rate (TPR) and false positive rate (FPR)
from each study to their logistic transforms. The method is based on the principle that there is a linear relationship between logit (TPR) and logit (FPR) where, using natural logs,
To estimate an SROC curve, we use the linear model: 
